BMEYE Receives CE Mark to Launch First Noninvasive Cardiovascular Monitor with Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Technology in Europe

Incorporating Masimo's Breakthrough Noninvasive Hemoglobin and Oxygen Saturation Measurements, ccNexfin Debuts to European Market

AMSTERDAM and IRVINE, California, January 21 - BMEYE B.V., the innovators of combined noninvasive, beat-to-beat blood
pressure and cardiac output monitoring, and Masimo (Nasdaq: MASI), the
inventor of Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion
pulse oximetry, jointly announce today CE Mark certification and the European
launch of the BMEYE ccNexfin-the first noninvasive cardiovascular monitor
with Masimo Rainbow SET Pulse CO-Oximetry technology. The combination of two
innovative noninvasive technologies-BMEYE for cardiovascular monitoring and
Masimo Rainbow SET for hemoglobin and oxygen saturation monitoring-provides
real-time, beat-to-beat measurements of cardiac, circulatory, and pulmonary
parameters, which may enable clinicians to detect impending cardiovascular
crisis before organ injury ensues.

The ccNexfin with Masimo Rainbow SET offers some of the most advanced
cardiovascular monitoring capabilities available today. It utilizes a single
sensor finger cuff (BMEYE) and finger sensor (Masimo Rainbow SET) to capture
and continuously measure beat-to-beat blood pressure (sys/dia), mean arterial
pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular
resistance (SVR), derivative of pressure (dP/dt), noninvasive hemoglobin
(SpHb), oxygen saturation (SpO2), and perfusion index (PI). This detailed
data allows clinicians to predict and proactively address the early signs of
hemodynamic instability during critical situations rather than reacting to
late indicators and their effects.

"ccNexfin is a unique noninvasive, beat-to-beat, and user friendly
cardiovascular monitor that delivers a patient's full hemodynamic profile
based on real-time data," stated Rob de Ree, CEO of BMEYE. "Masimo Rainbow
SET Pulse CO-Oximetry plays an integral role in the delivery of this rich
hemodynamic data stream by providing critical information about oxygen
delivery at the tissue level, which is an essential component of accurate
hemodynamic assessment."

Assessment of hemodynamic status is a cornerstone of critical care
medicine, routinely used to evaluate, diagnose, and direct therapy to manage
the care of at-risk and critically-ill patients. Hemodynamic monitoring-the
direct measurement of blood pressure inside the veins, heart and arteries in
relation to cardiac output and systemic vascular resistance-allows clinicians
to assess the cardiovascular system and identify early circulation changes
that reflect small changes in the way the heart is working to deliver blood
and oxygen to tissues and organs.

Hemodynamic monitoring has traditionally relied upon invasive, costly,
intermittent, or unreliable methods to assist clinicians in maintaining
adequate oxygen delivery and tissue perfusion to prevent hypoxia and its
irreversible damage. The integration of ccNexfin and Masimo Rainbow SET
technologies into the emergency department, intensive care units, and
anesthesiology care areas has the potential to facilitate earlier diagnosis
and the delivery of protocol- and goal-directed therapies that improve
patient safety and clinical outcomes.

Masimo Founder and CEO, Joe Kiani, stated, "The risks and costs
associated with invasive hemodynamic monitoring techniques leaves many
high-risk patients underserved at a time when assessing hemodynamic stability
is most needed. The synergistic combination of BMEYE and Rainbow SET means
that continuous, noninvasive hemodynamic monitoring can benefit more patients
at all points along the care path."

About BMEYE

BMEYE, a Dutch company based in Amsterdam, The Netherlands, develops
innovative medical devices with broad application in clinical settings that
require cardiovascular monitoring. Specifically, BMEYE produces patient
monitors that noninvasively measure continuous blood pressure and cardiac
output. BMEYE's mission: BMEYE is the premier provider and will set the
standard of noninvasive, beat-to-beat, user-friendly cardiovascular
monitoring systems, to improve patient care and reduce healthcare costs.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET(R), which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides
the most reliable SpO2 and pulse rate measurements even under the most
challenging clinical conditions, including patient motion and low peripheral
perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse
CO-Oximetry(TM), allowing noninvasive and continuous monitoring of blood
constituents that previously required invasive procedures, including total
hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin
(SpCO(R)), methemoglobin (SpMet(R)), and PVI(R), in addition to SpO2, pulse
rate, and perfusion index (PI). In 2009, Masimo introduced Masimo Rainbow
SET(R) Acoustic Monitoring(TM), the first-ever noninvasive and continuous
monitoring of acoustic respiration rate (RRa). Masimo's Rainbow platform
offers a breakthrough in patient safety by helping clinicians detect
life-threatening conditions and helping guide treatment options. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost
of Care by Taking Noninvasive Monitoring to New Sites and Applications."
Additional information about Masimo and its products may be found at
www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially
and adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks related
to our assumptions regarding the timing and market availability of ccNexfin
with Masimo Rainbow SET, risks related to our assumptions that the
integration of Masimo Rainbow SET with ccNexfin provides advanced noninvasive
and continuous hemodynamic monitoring capabilities that have the potential to
improve patient safety and outcomes by assisting in the delivery of
protocolized, goal-directed therapies, risks related to our belief that the
combination of Masimo Rainbow SET and ccNexfin will enable clinicians to
detect impending cardiovascular crisis before organ injury ensues, as well as
other factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"), which may
be obtained for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the "Risk
Factors" contained in our most recent reports filed with the SEC, whether as
a result of new information, future events or otherwise, except as may be
required under the applicable securities laws.

    Media Contacts:
    Dana Banks
    Masimo Corporation
    +1-949-297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and
Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and
Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.

Dana Banks of Masimo Corporation, +1-949-297-7348